Clinical outcome measures for cutaneous lupus erythematosus

Lupus

Volumn 19, Issue 9, 2010, Pages 1137-1143

  Albrecht, J ^a   Werth, V P ^b,c  

^a Jr Hospital of Cook County   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cutaneous lupus erythematosus; disease activity; patient outcome assessment; reproducibility of results; skin; validity

Indexed keywords

CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DISEASE ACTIVITY; DISEASE SEVERITY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SKIN LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS AS TOPIC; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955524409     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310370049     Document Type: Review

References (42)

1. Finlay AY Measurement of disease activity and outcome in atopic dermatitis. Br J Dermatol 1996 ; 135: 509-515.
2. National Cancer Institute Common toxicity criteria (CTC Version 2.0), http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf ( 1999, accessed April 2010 ).
3. Draft guidance for industry on Systemic Lupus Erythematosus: Developing drugs for treatment, http://www.fda.gov/cder/guidance/index.htm ( 2005, accessed May 2010 ).
4. Aringer M., Smolen JS Systemic lupus erythematosus - activity and outcome (article in German). Z Rheumatol 2006 ; 65: 103-106, 108-109.
5. Bombardier C., Gladman DD, Urowitz MB, Caron D., Chang CH Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 ; 35: 630-640.
6. Urowitz MB, Gladman DD, Tozman EC, Goldsmith CH The lupus activity criteria count (LACC). J Rheumatol 1984 ; 11: 783-787.
7. Gladman DD, Urowitz MB, Ong A., Gough J., MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 1996 ; 5: 190-195.
8. Liang MH, Socher SA, Larson MG, Schur PH Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989 ; 32: 1107-1118.
9. Parodi A., Massone C., Cacciapuoti M., et al. Measuring the activity of the disease in patients with cutaneous lupus erythematosus. Br J Dermatol 2000 ; 142: 457-460.
10. Faust HB, Gonin R., Chuang TY, Lewis CW, Melfi CA, Farmer ER Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997 ; 133: 1443-1448.
11. Albrecht J., Werth V. Outcome measures in cutaneous autoimmune diseases: dermatomyositis and lupus erythematosus. In: Sarzi-Puttini P, Doria A, Kuhn A, Girolomoni G, Asherson R (eds), The skin in systemic autoimmune diseases. Amsterdam: Elsevier Science; 2006. p. 207-220.
12. The Medical Algorithms Project Online MedalTM algorithms database, http://www.medal.org/visitor/login.aspx (accessed April 2010 ).
13. Albrecht J., Taylor L., Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005 ; 125: 889-894.
14. Krathen MS, Dunham J., Gaines E., et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008 ; 59: 338-344.
15. Bonilla-Martinez Z., Albrecht J., Taylor L., Okawa J., Werth V. The CLASI is a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus. Arthritis Rheum 2006 ; 54: S434.
16. Cook CH, Centner RL, Michaels SE An acne grading method using photographic standards. Arch Dermatol 1979 ; 115: 571-575.
17. Lidén S., Göransson K., Odsell L. Clinical evaluation in acne. Acta Derm Venereol Suppl (Stockh) 1980 ; 89 (Suppl): 47-52.
18. Layton AM, Henderson CA, Cunliffe WJ A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol 1994 ; 19: 303-308.
19. Yosipovitch G., Zucker I., Boner G., Gafter U., Shapira Y., David M. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001 ; 81: 108-111.
20. Berth-Jones J., Thompson J., Graham-Brown RA Evening primrose oil and atopic eczema. Lancet 1995 ; 345: 520.
21. European Task Force on Atopic Dermatitis. (1993). Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993 ; 186: 23-31.
22. Klein RQ, Bangert CA, Costner M., et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008 ; 159: 887-894.
23. Quinn AG, McLelland J., Essex T., Farr PM Quantification of contact allergic inflammation: a comparison of existing methods with a scanning laser Doppler velocimeter. Acta Derm Venereol 1993 ; 73: 21-25.
24. Charman CR, Venn AJ, Williams HC Measurement of body surface area involvement in atopic eczema: an impossible task? Br J Dermatol 1999 ; 140: 109-111.
25. Charman C., Williams H. Outcome measures of disease severity in atopic eczema. Arch Dermatol 2000 ; 136: 763-769.
26. Tiling-Grosse S., Rees J. Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol 1993 ; 128: 69-74.
27. Ramsay B., Lawrence CM Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991 ; 124: 565-570.
28. Lucky AW, Barber BL, Girman CJ, Williams J., Ratterman J., Waldstreicher J. A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 1996 ; 35: 559-565.
29. Williams HC Is a simple generic index of dermatologic disease severity an attainable goal? Arch Dermatol 1997 ; 133: 1451-1452.
30. Vardy D., Besser A., Amir M., Gesthalter B., Biton A., Buskila D. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002 ; 147: 736-742.
31. Krueger G., Koo J., Lebwohl M., Menter A., Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001 ; 137: 280-284.
32. Nichol MB, Margolies JE, Lippa E., Rowe M., Quell J. The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996 ; 10: 644-653.
33. Miller SF, Finley RK, Waltman M., Lincks J. Burn size estimate reliability: a study. J Burn Care Rehabil 1991 ; 12: 546-559.
34. Long CC, Mills CM, Finlay AY A practical guide to topical therapy in children. Br J Dermatol 1998 ; 138: 293-296.
35. Streiner DL, Norman GR Health measurement scales. A practical guide to their development and use, 2 nd ed. Oxford: Oxford University Press ; 1995.
36. Williams H. Objective measures of atopic dermatitis severity: in search of the holy Grail. Arch Dermatol 2003 ; 139: 1490-1492.
37. Kreuter A., Tomi NS, Weiner SM, Huger M., Altmeyer P., Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007 ; 156: 1321-1327.
38. Moghadam-Kia S., Chilek K., Gaines E., et al. Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009 ; 145: 255-260.
39. McHorney CA, Ware Jr JE, Raczek AE The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993 ; 31: 247-263.
40. Farrar JT, Berlin JA, Strom BL Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage 2003 ; 25: 406-411.
41. Carr AJ, Higginson IJ Are quality of life measures patient centred? BMJ 2001 ; 322: 1357-1360.
42. Gaines E., Bonilla-Martinez Z., Albrecht J., et al. Quality of life and disease severity in a cutaneous lupus erythematosus pilot study. Arch Dermatol 2008 ; 144: 1061-1062.